Dr. Zwicker joined the Technology Development Office in April 2016. Ken is responsible for all intellectual property and technology licensing matters arising from the Boston University Charles River Campus, the Boston University Medical School, the Goldman School of Dental Medicine, and the Boston Medical Center. Ken is an experienced patent attorney across all areas of technology, with particular expertise in life sciences intellectual property. Ken has extensive experience in both private practice and as in-house counsel.
Before joining the OTD, Ken was Partner at a major Boston law firm, where he counseled a broad spectrum of clients from fortune 200 companies, to academic institutions, to local start-ups and non-profit organizations in the areas of intellectual property assessment, patent strategy, prosecution, protection, licensing, acquisition, and enforcement. Prior to that, Ken was in-house counsel at Abbott Labs. At Abbott, Ken served as Division Patent Counsel, and headed the patent department of Abbott Bioresearch Center (now AbbVie). In that role, Ken directed the Abbott Labs immunoscience pharmaceutical products patent portfolio, including Abbott’s blockbuster drug, Humira®, the first fully human therapeutic antibody. In addition, Ken established and directed Abbott Labs global intellectual property strategy for therapeutic biologics R&D, process science, and commercial manufacture.
Ken earned his J.D. from Suffolk University Law School. Before becoming a patent attorney, Ken was a post-doctoral research associate at the Whitehead Institute for Biomedical Research at MIT. Ken earned his Ph.D. in biology from Boston University, and Bachelor of Science degree from Kent State University. Ken remains an active member of several scientific and legal associations.
Ken is a registered attorney with the United States Patent and Trademark Office (USPTO). He is licensed to practice law in the Commonwealth of Massachusetts, and is admitted to the US District Court for the District of Massachusetts, U.S. Court of Appeals for the First Circuit, and the U.S. Court of Appeals for the Federal Circuit.